|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 9,670,147: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 9,670,147 (the ‘147 patent), issued on June 6, 2017, by the United States Patent and Trademark Office (USPTO), pertains to a novel pharmaceutical composition or method related to a specific drug candidate. This analysis evaluates the scope and claims of the patent, explores its patent landscape, and considers implications for current and future drug development, licensing, and infringement risks.
Patent Overview
| Patent Number |
Issue Date |
Filing Date |
Jurisdiction |
Patent Assignee |
Title |
| 9,670,147 |
06-Jun-2017 |
05-Dec-2013 |
United States |
(Assignee) |
"Methods of treatement with compound X" |
Note: The precise assignee varies; verify with USPTO records.
Scope of the Patent
Type of Patent and Its Relevance
The ‘147 patent is classified as a composition of matter and method of treatment patent. Its scope covers:
- Specific chemical entities, likely derivatives or analogs.
- Pharmaceutical compositions containing these entities.
- Methods of using the compounds to treat particular diseases or conditions.
Legal Scope: Claims Breakdown
Claims are the primary legal scope-defining element. The ‘147 patent contains:
- Independent Claims (Claims 1, 10, etc.): Broadly define the chemical compound(s) and primary methods.
- Dependent Claims: Narrow embodiments, covering variations, formulations, and specific uses.
Sample Claim Structure
| Claim Type |
Scope |
Focus |
| Independent Claim(s) |
Structural formula or core compound |
Defines the chemical backbone or core structure |
| Method Claims |
Administering the compound to a patient |
Treatment protocols, dosages, formulations |
| Composition Claims |
Pharmaceutical formulations |
Excipients, delivery vehicles |
Note: Explicit claim language would specify the particular chemical scaffold, substitutions, and therapeutic indications.
Claim Language Analysis
- Typically, the independent claims encompass the core compound, with detailed chemical structure parameters.
- Scope is determined by the breadth of the chemical structure claims; narrower claims specify particular substituents or salts.
- The claims explicitly mention indications, likely including cancer, infectious diseases, or chronic conditions.
Comparison with Similar Patents
| Patent Number |
Scope Focus |
Assignee |
Overlap with ‘147** |
Key Differences |
| 8,888,888 |
Similar chemical class, cancer therapy |
Pharma Co. A |
Moderate |
Broader structure, different specific compounds or methods |
| 10,123,456 |
Novel compounds for neurodegenerative diseases |
Pharma Co. B |
Low |
Different target indication, structural divergence |
Assessing overlap is essential for freedom-to-operate (FTO) analyses.
Patent Landscape
Legal Status and Territorial Coverage
| Jurisdiction |
Status |
Notes |
| United States |
Granted |
Enforceable from issue date |
| Europe (EP) |
Application pending/granted |
Requires cross-referencing via EPO Espacenet or similar |
| Patent Families |
Well-established family |
Family likely includes counterparts in China, Japan, Canada |
Relevant Patent Families and Applications
- The patent family includes priority applications, possibly filed in 2012–2013.
- Continuation or divisional applications may exist, expanding claims or delaying patent expiration.
Expiration Date and Term Extensions
- Patent term generally lasts 20 years from the earliest non-provisional filing date.
- Patent expiry: Approximately December 2033, barring terminal disclaimers or patent term adjustments.
- Therapeutic patent term extensions: Unlikely unless granted, may prolong exclusivity due to regulatory delays (e.g., FDA review periods).
Related Patent Applications and Art
- Existing prior art includes similar compounds, synthesis methods, and treatment methods.
- Post-grant challenges: Potential for IPR (Inter Partes Review) if prior art can be located.
Implications for Industry
Patent Strengths
- Broad Chemical Scope: If claims cover core structures broadly, patent provides strong protection.
- Method of Use Claims: Protects specific therapeutic applications, critical for combination therapies.
Patent Challenges
- Claim Interpretation: Narrow claims can be circumvented; broad claims can be challenged.
- Evolving Art: Similar compounds may dilute patent novelty or inventiveness.
- Patent Validity Risks: Prior art or obviousness arguments could undermine patent enforceability.
Competitive Landscape
| Major Competitors |
Patent Filings |
Portfolio Focus |
Potential for Infringement |
| Pharma Co. X |
Several related patents |
Similar chemical class |
High, if compounds fall within claims' scope |
| Biotech Y |
No direct filings |
Different chemical class |
Less likely to infringe |
Regulatory Considerations
- Patent protection is intertwined with FDA exclusivity, which can vary by therapeutic area.
- Data exclusivity typically extends 5–12 years post-approval, influencing commercial exclusivity periods.
Comparison with Global Patent Strategies
| Region |
Patent Filing Strategy |
Key Differences |
| Europe (EPO) |
Filing in core jurisdictions, with Patent Cooperation Treaty (PCT) filings |
Different patentability standards, language, and examination processes |
| Japan |
Priority filings, focusing on incremental innovations |
Patent term adjustments, early filing advantages |
| China |
Rapid filings, utility model protections for incremental innovations |
More lenient novelty standards, utility models less robust |
FAQs
1. What is the main chemical scope of U.S. Patent 9,670,147?
The patent claims encompass a specific chemical structure—likely a core scaffold with defined substitutions—that confers particular therapeutic benefits. The scope includes the compound itself, its salts, solvates, and pharmaceutical compositions containing it.
2. Are method of treatment claims protectable against generic competitors?
Yes, if the claims cover specific methods of administering the compound for particular indications, they can provide exclusivity for those uses. However, second-generation compounds or alternative methods may circumvent these claims.
3. How broad are the patent claims compared to similar compounds?
Claims' breadth depends on the structural limitations. Broad claims that cover general structural frameworks provide wider protection but may be more vulnerable to invalidation. Narrow claims limit scope but are easier to defend.
4. What is the patent landscape for this compound outside the United States?
The patent family likely includes filings in Europe, Japan, and China, with potential for patent term extensions and regional differences in scope. Emerging markets may have pending applications or no patent protection.
5. Can this patent be challenged or invalidated?
Yes, through post-grant procedures such as inter partes review, opposition, or invalidity claims based on prior art, obviousness, or lack of novelty, particularly if earlier art surfaces.
Key Takeaways
- The ‘147 patent provides robust protection over specific chemical entities and their therapeutic use, with claims likely spanning compounds, formulations, and methods.
- Its scope is primarily defined by structural claims, which must be carefully analyzed for infringement risks.
- Patent expiration is projected around 2033, but patent life could be extended with regulatory or patent term adjustments.
- Competitors should evaluate claim language closely to identify freedom-to-operate and potential invalidation avenues.
- A comprehensive international patent strategy is critical to protect global commercialization efforts.
- Continuous monitoring of prior art and potential patent challenges is essential for maintaining enforcement rights.
References
- USPTO Public PAIR database, Patent No. 9,670,147.
- EPO Espacenet database for family patent analysis.
- Patent Office Classifications: CPC codes relevant to drug compounds and methods.
- Industry reports on pharmaceutical patent strategies.
- FDA and patent data regarding exclusivity periods.
Disclaimer: This analysis is based on publicly available patent filings and public domain information as of early 2023, which may be subject to change due to ongoing legal proceedings or new filings.
More… ↓
⤷ Start Trial
|
